CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that its presentation at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference will be webcast live and may be accessed by visiting the Investors section of the Company’s website, http://www.millennium.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will include an overview of the Company, an update on clinical trials for VELCADE(R) (bortezomib) for Injection and other product candidates, and a review of upcoming milestones. The presentation will be delivered at 9:20 a.m. ET (2:20 p.m. GMT) on Thursday, September 20, 2007 from the Merrill Lynch Financial Centre in London, England. The presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company’s website is http://www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com.
Contact:
Kyle Kuvalanka
(617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Kyle Kuvalanka of Millennium Pharmaceuticals, Inc.,+1-617-761-4734
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html/
